Nanjing Iaso/Innovent to Sponsor China Trial of Fully Human BCMA CAR-T Next Year and are Guiding Towards 2021 Approval
October 31, 2019 Impact: High China regulators have cleared the IND for the fully human BCMA CAR-T, CT-103A, in development by Nanjing Iaso and Innovent Biologics. In the recent issue of BioWorld (pages 1 & 6), Brian Hall, VP of Business Development at Iaso, stated that a phase 1b/2 trial to confirm the recommended phase […]